Haftmann Richard J, Pineda Erika May, Hall Brent A, Wilson Machelle D, Mateev Stephanie N
Department of Pharmacy Services (RJH, BAH), University of California, Davis Health, Sacramento, CA.
Department of Pharmacy Services (EMP), Children's Hospital of Philadelphia, Philadelphia, PA.
J Pediatr Pharmacol Ther. 2023;28(3):228-234. doi: 10.5863/1551-6776-28.3.228. Epub 2023 Jun 2.
To compare unfractionated heparin (UFH) monitoring using time in therapeutic range of activated partial thromboplastin time (aPTT) versus anti-factor Xa activity (anti-Xa) in children.
This retrospective chart review, with data between October 2015 and October 2019, included pediatric patients younger than 18 years on therapeutic UFH infusion with aPTT or anti-Xa monitoring. Patients receiving extracorporeal membrane oxygenation, dialysis, concomitant anticoagulants, prophylactic UFH, no stated goal, and UFH administered for less than 12 hours were excluded. The primary outcome compared the percentage of time in therapeutic range between aPTT and anti-Xa. Secondary outcomes included time to first therapeutic value, UFH infusion rates, mean rate adjustments, and adverse events.
A total of 65 patients were included, with 33 aPTT patients and 32 anti-Xa patients, representing 39 UFH orders in each group. Baseline characteristics were similar between groups, with an overall mean age of 1.4 years and mean weight of 6.7 kg. The anti-Xa cohort demonstrated a statistically significantly higher percentage of time in therapeutic range compared with the aPTT group (50.3% vs 26.9%, p = 0.002). The anti-Xa group also demonstrated a trend toward decreased time to first therapeutic value compared with aPTT (14 vs 23.2 hours, p = 0.12). Two patients in each group experienced new or worsening thrombosis. Six patients in the aPTT cohort experienced bleeding.
This study demonstrated greater time was spent within therapeutic range for children receiving UFH monitored with anti-Xa compared with aPTT. Future studies should assess clinical outcomes in a larger population.
比较在儿童中使用活化部分凝血活酶时间(aPTT)的治疗范围内时间与抗Xa因子活性(抗Xa)监测普通肝素(UFH)的情况。
这项回顾性病历审查纳入了2015年10月至2019年10月期间接受UFH治疗性输注并进行aPTT或抗Xa监测的18岁以下儿科患者。接受体外膜肺氧合、透析、同时使用抗凝剂、预防性UFH、未明确目标以及UFH使用时间少于12小时的患者被排除。主要结局比较了aPTT和抗Xa在治疗范围内的时间百分比。次要结局包括达到首次治疗值的时间、UFH输注速率、平均速率调整以及不良事件。
共纳入65例患者,其中33例采用aPTT监测,32例采用抗Xa监测,每组各有39次UFH医嘱。两组的基线特征相似,总体平均年龄为1.4岁,平均体重为6.7千克。与aPTT组相比,抗Xa队列在治疗范围内的时间百分比具有统计学显著更高(50.3%对26.9%,p = 0.002)。与aPTT相比,抗Xa组达到首次治疗值的时间也有缩短趋势(14小时对23.2小时,p = 0.12)。每组有2例患者出现新的或恶化的血栓形成。aPTT队列中有6例患者发生出血。
本研究表明,与aPTT监测相比,接受抗Xa监测UFH的儿童在治疗范围内花费的时间更多。未来研究应在更大规模人群中评估临床结局。